Wall Street analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks. Three analysts have issued estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). TG Therapeutics reported earnings of ($0.46) per share in the same quarter last year, which would indicate a positive year over year growth rate of 2.2%. The company is scheduled to announce its next earnings results on Thursday, March 14th.
On average, analysts expect that TG Therapeutics will report full-year earnings of ($2.03) per share for the current financial year, with EPS estimates ranging from ($2.10) to ($1.98). For the next fiscal year, analysts expect that the company will report earnings of ($1.60) per share, with EPS estimates ranging from ($2.06) to ($0.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%.
A number of research firms have issued reports on TGTX. ValuEngine downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, September 17th. Raymond James downgraded TG Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their price target for the company from $22.00 to $12.00 in a research note on Tuesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of TG Therapeutics in a research note on Friday, November 2nd. LADENBURG THALM/SH SH set a $27.00 price target on TG Therapeutics and gave the company a “buy” rating in a research note on Wednesday, September 26th. Finally, Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Friday, November 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $18.35.
A number of hedge funds have recently added to or reduced their stakes in TGTX. BlackRock Inc. lifted its position in shares of TG Therapeutics by 8.3% during the 3rd quarter. BlackRock Inc. now owns 4,420,852 shares of the biopharmaceutical company’s stock worth $24,757,000 after buying an additional 339,802 shares in the last quarter. RA Capital Management LLC lifted its position in shares of TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock worth $56,266,000 after buying an additional 1,806,452 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock worth $17,125,000 after buying an additional 268,483 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of TG Therapeutics by 2,148.1% during the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock worth $11,686,000 after buying an additional 849,233 shares in the last quarter. Finally, Highland Capital Management LP lifted its position in shares of TG Therapeutics by 60.5% during the 3rd quarter. Highland Capital Management LP now owns 753,151 shares of the biopharmaceutical company’s stock worth $4,218,000 after buying an additional 283,910 shares in the last quarter. Institutional investors and hedge funds own 57.30% of the company’s stock.
Shares of TGTX traded up $0.04 during trading hours on Thursday, hitting $5.04. The stock had a trading volume of 1,552,400 shares, compared to its average volume of 1,348,560. The company has a market cap of $414.49 million, a PE ratio of -2.64 and a beta of 1.72. TG Therapeutics has a 1-year low of $4.20 and a 1-year high of $17.35.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Featured Article: Yield Curve
Get a free copy of the Zacks research report on TG Therapeutics (TGTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.